The M&A Hunter

The M&A Hunter

Founders call review

5/30/2026

The M&A Hunter's avatar
The M&A Hunter
May 30, 2026
∙ Paid

ASCO

GLUE | Monte Rosa Therapeutics — MRT-2359 + enzalutamide | mCRPC

Population is heavily pretreated — 75% had prior second-gen AR inhibitor, 80% taxane, 55% Pluvicto. The key subgroup is AR-mutant:…

This post is for subscribers in the Founding Member plan

Already in the Founding Member plan? Sign in
© 2026 The M&A Hunter · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture